KR20020021811A - 환자 표본에서 지혈 기능장애의 존재를 예견하기 위한 방법 - Google Patents
환자 표본에서 지혈 기능장애의 존재를 예견하기 위한 방법 Download PDFInfo
- Publication number
- KR20020021811A KR20020021811A KR1020027001897A KR20027001897A KR20020021811A KR 20020021811 A KR20020021811 A KR 20020021811A KR 1020027001897 A KR1020027001897 A KR 1020027001897A KR 20027001897 A KR20027001897 A KR 20027001897A KR 20020021811 A KR20020021811 A KR 20020021811A
- Authority
- KR
- South Korea
- Prior art keywords
- reagent
- formation
- precipitate
- patient
- sample
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 238000000034 method Methods 0.000 title claims abstract description 87
- 230000004064 dysfunction Effects 0.000 title description 4
- 239000013610 patient sample Substances 0.000 title description 2
- 229940030225 antihemorrhagics Drugs 0.000 title 1
- 230000000025 haemostatic effect Effects 0.000 title 1
- 238000012360 testing method Methods 0.000 claims abstract description 78
- 239000002244 precipitate Substances 0.000 claims abstract description 67
- 230000006881 hemostatic dysfunction Effects 0.000 claims abstract description 50
- 208000007536 Thrombosis Diseases 0.000 claims abstract description 7
- 230000000740 bleeding effect Effects 0.000 claims abstract description 4
- 239000003153 chemical reaction reagent Substances 0.000 claims description 83
- 230000015572 biosynthetic process Effects 0.000 claims description 57
- 102100032752 C-reactive protein Human genes 0.000 claims description 44
- 108010074051 C-Reactive Protein Proteins 0.000 claims description 43
- 102000004169 proteins and genes Human genes 0.000 claims description 37
- 108090000623 proteins and genes Proteins 0.000 claims description 37
- 230000008859 change Effects 0.000 claims description 34
- 238000005259 measurement Methods 0.000 claims description 33
- 108010073385 Fibrin Proteins 0.000 claims description 30
- 102000009123 Fibrin Human genes 0.000 claims description 30
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 claims description 30
- 229950003499 fibrin Drugs 0.000 claims description 30
- 239000003112 inhibitor Substances 0.000 claims description 24
- 238000002834 transmittance Methods 0.000 claims description 23
- 238000006116 polymerization reaction Methods 0.000 claims description 21
- 230000015271 coagulation Effects 0.000 claims description 20
- 238000005345 coagulation Methods 0.000 claims description 20
- 230000035602 clotting Effects 0.000 claims description 17
- 230000003287 optical effect Effects 0.000 claims description 17
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 16
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 16
- 230000005540 biological transmission Effects 0.000 claims description 16
- 229910052791 calcium Inorganic materials 0.000 claims description 16
- 239000011575 calcium Substances 0.000 claims description 16
- 210000004369 blood Anatomy 0.000 claims description 15
- 239000008280 blood Substances 0.000 claims description 15
- 150000001768 cations Chemical class 0.000 claims description 14
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims description 13
- 229960002897 heparin Drugs 0.000 claims description 13
- 229920000669 heparin Polymers 0.000 claims description 13
- 230000001965 increasing effect Effects 0.000 claims description 12
- KWPACVJPAFGBEQ-IKGGRYGDSA-N (2s)-1-[(2r)-2-amino-3-phenylpropanoyl]-n-[(3s)-1-chloro-6-(diaminomethylideneamino)-2-oxohexan-3-yl]pyrrolidine-2-carboxamide Chemical compound C([C@@H](N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)CCl)C1=CC=CC=C1 KWPACVJPAFGBEQ-IKGGRYGDSA-N 0.000 claims description 11
- 230000007423 decrease Effects 0.000 claims description 11
- 229910052751 metal Inorganic materials 0.000 claims description 11
- 239000002184 metal Substances 0.000 claims description 11
- 238000011282 treatment Methods 0.000 claims description 11
- 108700028909 Serum Amyloid A Proteins 0.000 claims description 10
- 102000054727 Serum Amyloid A Human genes 0.000 claims description 10
- 238000007711 solidification Methods 0.000 claims description 10
- 230000008023 solidification Effects 0.000 claims description 10
- 230000036962 time dependent Effects 0.000 claims description 9
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 8
- 239000004019 antithrombin Substances 0.000 claims description 8
- 230000001939 inductive effect Effects 0.000 claims description 8
- 229910052742 iron Inorganic materials 0.000 claims description 8
- 229910052749 magnesium Inorganic materials 0.000 claims description 8
- 239000011777 magnesium Substances 0.000 claims description 8
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 claims description 8
- 238000012544 monitoring process Methods 0.000 claims description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 7
- 102000007625 Hirudins Human genes 0.000 claims description 7
- 108010007267 Hirudins Proteins 0.000 claims description 7
- 229940006607 hirudin Drugs 0.000 claims description 7
- WQPDUTSPKFMPDP-OUMQNGNKSA-N hirudin Chemical compound C([C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(OS(O)(=O)=O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H]1NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H]2CSSC[C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@H](C(NCC(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N2)=O)CSSC1)C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)[C@@H](C)O)CSSC1)C(C)C)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 WQPDUTSPKFMPDP-OUMQNGNKSA-N 0.000 claims description 7
- 238000003018 immunoassay Methods 0.000 claims description 7
- 238000006243 chemical reaction Methods 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 6
- 239000003446 ligand Substances 0.000 claims description 6
- 239000013049 sediment Substances 0.000 claims description 6
- 229940079593 drug Drugs 0.000 claims description 5
- 241001465754 Metazoa Species 0.000 claims description 4
- 206010040047 Sepsis Diseases 0.000 claims description 4
- 208000014674 injury Diseases 0.000 claims description 4
- 230000008733 trauma Effects 0.000 claims description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 3
- 238000002835 absorbance Methods 0.000 claims description 3
- 239000003242 anti bacterial agent Substances 0.000 claims description 3
- 230000003247 decreasing effect Effects 0.000 claims description 3
- 230000002757 inflammatory effect Effects 0.000 claims description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims description 2
- 229940088710 antibiotic agent Drugs 0.000 claims description 2
- 230000007850 degeneration Effects 0.000 claims description 2
- 230000004968 inflammatory condition Effects 0.000 claims description 2
- 239000002547 new drug Substances 0.000 claims description 2
- 239000011780 sodium chloride Substances 0.000 claims description 2
- 238000001356 surgical procedure Methods 0.000 claims description 2
- 206010043554 thrombocytopenia Diseases 0.000 claims description 2
- 230000007704 transition Effects 0.000 claims description 2
- 229910021645 metal ion Inorganic materials 0.000 claims 10
- 229910052788 barium Inorganic materials 0.000 claims 7
- DSAJWYNOEDNPEQ-UHFFFAOYSA-N barium atom Chemical compound [Ba] DSAJWYNOEDNPEQ-UHFFFAOYSA-N 0.000 claims 7
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims 3
- 206010061818 Disease progression Diseases 0.000 claims 1
- 102000000589 Interleukin-1 Human genes 0.000 claims 1
- 108010002352 Interleukin-1 Proteins 0.000 claims 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims 1
- 230000003115 biocidal effect Effects 0.000 claims 1
- 229960000182 blood factors Drugs 0.000 claims 1
- 239000004202 carbamide Substances 0.000 claims 1
- 230000015556 catabolic process Effects 0.000 claims 1
- 238000006731 degradation reaction Methods 0.000 claims 1
- 230000005750 disease progression Effects 0.000 claims 1
- 238000000605 extraction Methods 0.000 claims 1
- 230000003169 placental effect Effects 0.000 claims 1
- 238000009256 replacement therapy Methods 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 239000003634 thrombocyte concentrate Substances 0.000 claims 1
- 210000004291 uterus Anatomy 0.000 claims 1
- 238000005303 weighing Methods 0.000 claims 1
- 208000009190 disseminated intravascular coagulation Diseases 0.000 abstract description 72
- 208000032843 Hemorrhage Diseases 0.000 abstract description 3
- 208000034158 bleeding Diseases 0.000 abstract description 2
- 239000000523 sample Substances 0.000 description 44
- 210000002381 plasma Anatomy 0.000 description 30
- 230000002159 abnormal effect Effects 0.000 description 28
- 108010094028 Prothrombin Proteins 0.000 description 25
- 102100027378 Prothrombin Human genes 0.000 description 25
- 229940039716 prothrombin Drugs 0.000 description 25
- 230000035699 permeability Effects 0.000 description 20
- 238000003556 assay Methods 0.000 description 14
- 239000003154 D dimer Substances 0.000 description 11
- 230000005856 abnormality Effects 0.000 description 11
- 108010052295 fibrin fragment D Proteins 0.000 description 11
- 230000035945 sensitivity Effects 0.000 description 10
- 238000003745 diagnosis Methods 0.000 description 9
- 238000002965 ELISA Methods 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 7
- 230000004044 response Effects 0.000 description 7
- 230000001594 aberrant effect Effects 0.000 description 5
- 238000007792 addition Methods 0.000 description 5
- 230000023555 blood coagulation Effects 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 230000002439 hemostatic effect Effects 0.000 description 5
- 238000011068 loading method Methods 0.000 description 5
- 206010053567 Coagulopathies Diseases 0.000 description 4
- 108010049003 Fibrinogen Proteins 0.000 description 4
- 102000008946 Fibrinogen Human genes 0.000 description 4
- 239000012614 Q-Sepharose Substances 0.000 description 4
- 238000004587 chromatography analysis Methods 0.000 description 4
- 229940012952 fibrinogen Drugs 0.000 description 4
- 238000004508 fractional distillation Methods 0.000 description 4
- 230000000977 initiatory effect Effects 0.000 description 4
- 239000004816 latex Substances 0.000 description 4
- 229920000126 latex Polymers 0.000 description 4
- 238000011084 recovery Methods 0.000 description 4
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 3
- 108010090444 Innovin Proteins 0.000 description 3
- 108090000190 Thrombin Proteins 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 230000003321 amplification Effects 0.000 description 3
- 239000001110 calcium chloride Substances 0.000 description 3
- 229910001628 calcium chloride Inorganic materials 0.000 description 3
- 230000004069 differentiation Effects 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 238000003199 nucleic acid amplification method Methods 0.000 description 3
- 239000008188 pellet Substances 0.000 description 3
- 229960004072 thrombin Drugs 0.000 description 3
- PGOHTUIFYSHAQG-LJSDBVFPSA-N (2S)-6-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-1-[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-4-methylsulfanylbutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]propanoyl]pyrrolidine-2-carbonyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]-3-sulfanylpropanoyl]amino]-4-methylsulfanylbutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-hydroxybutanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-oxopentanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-oxopentanoyl]amino]-3-phenylpropanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-oxobutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-4-carboxybutanoyl]amino]-5-oxopentanoyl]amino]hexanoic acid Chemical compound CSCC[C@H](N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(O)=O PGOHTUIFYSHAQG-LJSDBVFPSA-N 0.000 description 2
- 206010003658 Atrial Fibrillation Diseases 0.000 description 2
- 102000007474 Multiprotein Complexes Human genes 0.000 description 2
- 108010085220 Multiprotein Complexes Proteins 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 2
- 206010051379 Systemic Inflammatory Response Syndrome Diseases 0.000 description 2
- 229940122388 Thrombin inhibitor Drugs 0.000 description 2
- 108010000499 Thromboplastin Proteins 0.000 description 2
- 102000002262 Thromboplastin Human genes 0.000 description 2
- 238000005571 anion exchange chromatography Methods 0.000 description 2
- 239000003146 anticoagulant agent Substances 0.000 description 2
- 229940127219 anticoagulant drug Drugs 0.000 description 2
- 238000000149 argon plasma sintering Methods 0.000 description 2
- 230000002051 biphasic effect Effects 0.000 description 2
- 239000000701 coagulant Substances 0.000 description 2
- 238000007820 coagulation assay Methods 0.000 description 2
- 230000021615 conjugation Effects 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 238000001152 differential interference contrast microscopy Methods 0.000 description 2
- 238000002523 gelfiltration Methods 0.000 description 2
- 230000023597 hemostasis Effects 0.000 description 2
- 238000003119 immunoblot Methods 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 239000003999 initiator Substances 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 208000019423 liver disease Diseases 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000004393 prognosis Methods 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 229910052710 silicon Inorganic materials 0.000 description 2
- 239000010703 silicon Substances 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 239000007790 solid phase Substances 0.000 description 2
- 239000003868 thrombin inhibitor Substances 0.000 description 2
- 0 CCC1([C@@]2C1CC(*)C2)C(C1[C@@](C2)C2C1)=C=* Chemical compound CCC1([C@@]2C1CC(*)C2)C(C1[C@@](C2)C2C1)=C=* 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 208000027205 Congenital disease Diseases 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 208000037273 Pathologic Processes Diseases 0.000 description 1
- 101800004937 Protein C Proteins 0.000 description 1
- 102000017975 Protein C Human genes 0.000 description 1
- 229940096437 Protein S Drugs 0.000 description 1
- 102000029301 Protein S Human genes 0.000 description 1
- 108010066124 Protein S Proteins 0.000 description 1
- 101800001700 Saposin-D Proteins 0.000 description 1
- 239000012506 Sephacryl® Substances 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 101000712605 Theromyzon tessulatum Theromin Proteins 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 208000037919 acquired disease Diseases 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 238000011256 aggressive treatment Methods 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 229910001422 barium ion Inorganic materials 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 208000015294 blood coagulation disease Diseases 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 230000009852 coagulant defect Effects 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 239000004023 fresh frozen plasma Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 206010022694 intestinal perforation Diseases 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000013178 mathematical model Methods 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000008383 multiple organ dysfunction Effects 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 230000004768 organ dysfunction Effects 0.000 description 1
- 230000009054 pathological process Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000008447 perception Effects 0.000 description 1
- 206010034674 peritonitis Diseases 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 201000011461 pre-eclampsia Diseases 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 229960000856 protein c Drugs 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 208000037974 severe injury Diseases 0.000 description 1
- 230000009528 severe injury Effects 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- 239000008279 sol Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 1
- 229940038773 trisodium citrate Drugs 0.000 description 1
- 235000019263 trisodium citrate Nutrition 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/483—Physical analysis of biological material
- G01N33/487—Physical analysis of biological material of liquid biological material
- G01N33/49—Blood
- G01N33/4905—Determining clotting time of blood
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/96—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation using ion-exchange
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Food Science & Technology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Biophysics (AREA)
- Ecology (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Diabetes (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/372,954 US6429017B1 (en) | 1999-02-04 | 1999-08-12 | Method for predicting the presence of haemostatic dysfunction in a patient sample |
| US09/372,954 | 1999-08-12 | ||
| PCT/US2000/021022 WO2001013125A1 (en) | 1999-08-12 | 2000-08-02 | A method for predicting the presence of haemostatic dysfunction in a patient sample |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20020021811A true KR20020021811A (ko) | 2002-03-22 |
Family
ID=23470305
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020027001897A Ceased KR20020021811A (ko) | 1999-08-12 | 2000-08-02 | 환자 표본에서 지혈 기능장애의 존재를 예견하기 위한 방법 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US6429017B1 (enExample) |
| EP (1) | EP1200837A4 (enExample) |
| JP (1) | JP4733326B2 (enExample) |
| KR (1) | KR20020021811A (enExample) |
| AU (1) | AU6617900A (enExample) |
| CA (1) | CA2380622C (enExample) |
| WO (1) | WO2001013125A1 (enExample) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6429017B1 (en) * | 1999-02-04 | 2002-08-06 | Biomerieux | Method for predicting the presence of haemostatic dysfunction in a patient sample |
| EP1522860A1 (en) * | 1999-02-04 | 2005-04-13 | bioMérieux, Inc. | A method and apparatus for predicting the presence of haemostatic dysfunction in a patient sample |
| ATE282208T1 (de) * | 1999-02-04 | 2004-11-15 | Bio Merieux Inc | Verfahren und vorrichtung zum vorhersagen von haemostatischer funktionsstörung in patientenproben |
| AUPP971299A0 (en) * | 1999-04-12 | 1999-05-06 | South Eastern Sydney Area Health Service | Procoagulant assay |
| US7179612B2 (en) * | 2000-06-09 | 2007-02-20 | Biomerieux, Inc. | Method for detecting a lipoprotein-acute phase protein complex and predicting an increased risk of system failure or mortality |
| DE60112949T2 (de) * | 2000-06-09 | 2006-05-18 | Biomerieux, Inc. | Verfahren zum nachweis eines lipoprotein-akutphaseprotein-komplexes |
| EP1436628A2 (en) * | 2001-06-29 | 2004-07-14 | BioMerieux, Inc. | A method for predicting an increased likelihood of antiphospholipid syndrome in a patient |
| US7282368B2 (en) * | 2002-02-27 | 2007-10-16 | Biomerieux, Inc. | Method for diagnosing and monitoring hemostatic dysfunction, severe infection and systematic inflammatory response syndrome |
| ES2275980T3 (es) * | 2002-08-09 | 2007-06-16 | Dade Behring Marburg Gmbh | Combinacion de proteina c reactiva y dimero-d para el diagnostico de trombosis venosa profunda (tvp). |
| AU2003277398A1 (en) * | 2002-10-15 | 2004-05-04 | The University Of Tennessee Research Foundation | Methods for assessment of platelet aggregation |
| CA2505843A1 (en) | 2002-11-12 | 2004-05-27 | Becton, Dickinson And Company | Diagnosis of sepsis or sirs using biomarker profiles |
| EP1573054A4 (en) * | 2002-11-12 | 2005-12-28 | Becton Dickinson Co | DIAGNOSIS FOR SEPTICEMIA OR SIRS USING BIOMARKER PROFILES |
| EP1565570A4 (en) | 2002-11-12 | 2005-12-28 | Becton Dickinson Co | DIAGNOSIS OF SEPTICEMIA OR SIRS USING BIOMARKER PROFILES |
| GB2404981A (en) | 2003-08-15 | 2005-02-16 | Univ Geneve | Diagnostic method for stroke |
| EP1828783A1 (en) * | 2004-12-01 | 2007-09-05 | BioMerieux, Inc. | Method for diagnosing critically ill patients |
| US20060157647A1 (en) * | 2005-01-18 | 2006-07-20 | Becton, Dickinson And Company | Multidimensional liquid chromatography/spectrometry |
| EP1869463A4 (en) | 2005-04-15 | 2010-05-05 | Becton Dickinson Co | SEPSIS DIAGNOSIS |
| RU2360610C1 (ru) * | 2008-01-29 | 2009-07-10 | Федеральное государственное учреждение "Ивановский научно-исследовательский институт материнства и детства имени В.Н. Городкова Федерального агентства по высокотехнологичной медицинской помощи" | Способ прогнозирования возникновения осложнений у женщин с климактерическим синдромом на фоне заместительной гормональной терапии |
| US8548935B2 (en) * | 2008-02-14 | 2013-10-01 | Orion Diagnostica Oy | Predicting a future property using reagents by measuring properties at points in time |
| WO2009123737A2 (en) | 2008-04-03 | 2009-10-08 | Becton, Dickinson And Company | Advanced detection of sepsis |
| DE102008022884A1 (de) * | 2008-05-08 | 2009-11-12 | Zander, Rolf, Prof. Dr.Med. | Vorrichtung und Verfahren für die Blutgerinnungsdiagnostik |
| GB2547930A (en) * | 2016-03-03 | 2017-09-06 | Sepsense Ltd | Assay device |
| EP3519828A4 (en) | 2016-09-29 | 2020-06-03 | Animantis, LLC | METHOD AND DEVICE FOR EVALUATING IMMUNE SYSTEM ACTIVITY AND THERAPEUTIC EFFECTIVENESS |
| CN108344875B (zh) * | 2017-01-22 | 2021-11-02 | 上海长岛生物技术有限公司 | 提高活化部分凝血活酶时间试剂对肝素敏感性的方法及用途 |
Family Cites Families (100)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2458287A (en) * | 1944-08-31 | 1949-01-04 | Signode Steel Strapping Co | Snubber plate |
| US3307392A (en) | 1964-05-04 | 1967-03-07 | Research Corp | Automatic prothrombin timer apparatus and method |
| US3458287A (en) | 1965-04-29 | 1969-07-29 | Medical Laboratory Automation | Method and means of determining endpoint times in blood clotting tests |
| US3658480A (en) | 1970-04-13 | 1972-04-25 | Bio Data Corp | Coagulation timing apparatus, and method |
| US4047890A (en) | 1973-11-01 | 1977-09-13 | Bio/Data Corporation | Method and apparatus for determining deficiencies in enzymatic reactors particularly clotting factor levels in blood plasmas |
| SU590665A1 (ru) | 1976-02-11 | 1978-01-30 | Новосибирский государственный медицинский институт | Способ исследовани процесса свертывани крови |
| US4040788A (en) * | 1976-04-05 | 1977-08-09 | Sanford L. Simons | Apparatus, instrumentation, and method for comparing samples |
| US4157871A (en) * | 1976-06-02 | 1979-06-12 | Beckman Instruments, Inc. | System for rate immunonephelometric analysis |
| DE2635081C3 (de) | 1976-08-04 | 1980-08-07 | Bio/Data Corp., Willow Grove, Pa. (V.St.A.) | Verfahren und Vorrichtung zur Bestimmung von Blutplasma-Gerinnungsfaktorpegeln |
| FR2364453A1 (fr) | 1976-09-08 | 1978-04-07 | Lacombe Pierre | Dispositif electronique apportant un perfectionnement aux appareils destines a analyser la coagulation sanguine : prothrombinometre citrate-oxalate |
| US4199748A (en) | 1976-11-01 | 1980-04-22 | Rush-Presbyterian-St. Luke's Medical Center | Automated method and apparatus for classification of cells with application to the diagnosis of anemia |
| JPS5451893A (en) | 1977-09-30 | 1979-04-24 | Sankyo Co | Measuring of blood coagulating time |
| JPS5822703B2 (ja) | 1978-08-30 | 1983-05-10 | 三共株式会社 | 血液凝固測定方法 |
| US4289498A (en) | 1979-01-08 | 1981-09-15 | Ortho Diagnostics, Inc. | One-stage prothrombin assay and compositions useful therein |
| AU543007B2 (en) * | 1980-04-15 | 1985-03-28 | Technicon Instruments Corportion | Agglutination immunoassay |
| US4766083A (en) | 1982-04-04 | 1988-08-23 | Wako Pure Chemical Industries, Ltd. | Method for the photometric determination of biological agglutination |
| SU1076086A1 (ru) | 1982-12-28 | 1984-02-29 | Всесоюзный Научно-Исследовательский И Конструкторский Институт Медицинской Лабораторной Техники | Гемокоагулограф |
| US4705756A (en) | 1983-01-26 | 1987-11-10 | University Of Medicine And Dentistry Of New Jersey | Method of determining the existence and/or the monitoring of a pathological condition in a mammal |
| EP0115459A3 (en) | 1983-01-26 | 1986-11-20 | University Of Medicine And Dentistry Of New Jersey | Hematological prediction of sepsis and other disease states |
| JPS59203959A (ja) | 1983-05-04 | 1984-11-19 | Toa Medical Electronics Co Ltd | 血液凝固時間測定装置 |
| JPH0695095B2 (ja) | 1983-11-25 | 1994-11-24 | 株式会社島津製作所 | 全自動血液分析装置 |
| DE3502878A1 (de) | 1985-01-29 | 1986-07-31 | Boehringer Mannheim Gmbh, 6800 Mannheim | Verfahren zur bestimmung des fibrinolytischen zustands von plasma |
| JPS61272655A (ja) | 1985-05-28 | 1986-12-02 | Iryo Kogaku Kenkyusho:Kk | 血小板凝集能の定量的判定方法 |
| GB8516081D0 (en) | 1985-06-25 | 1985-07-31 | Ciba Geigy Ag | Assay & purification of amyloid components |
| US4902630A (en) | 1985-07-22 | 1990-02-20 | Abbott Laboratories | Fluorescence polarization immunoassy and reagents for measurement of c-reactive protein |
| AU633488B2 (en) | 1988-04-04 | 1993-02-04 | Northwestern University | Binding of immune complexes by modified forms of c-reactive protein |
| US5593897A (en) | 1988-04-04 | 1997-01-14 | Northwestern University | Binding of immune complexes by modified forms of C-reactive protein |
| US4965725B1 (en) | 1988-04-08 | 1996-05-07 | Neuromedical Systems Inc | Neural network based automated cytological specimen classification system and method |
| US5156974A (en) | 1988-05-27 | 1992-10-20 | Biodata Corporation | Method for determining the fibrinogen level of a blood sample |
| US5003065A (en) | 1988-06-14 | 1991-03-26 | Carey Merritt | Compounds and process for measuring c-reactive protein |
| US5697369A (en) | 1988-12-22 | 1997-12-16 | Biofield Corp. | Method and apparatus for disease, injury and bodily condition screening or sensing |
| DE3901458A1 (de) * | 1989-01-19 | 1990-07-26 | Behringwerke Ag | Verwendung von zwei- oder dreiwertigen kationen in immunchemischen tests |
| US5055412A (en) * | 1989-03-21 | 1991-10-08 | Proksch Gary J | Factor sensitive reagent for testing of blood coagulation containing ellagic acid and divalent metal ions and method of making the same |
| US5500345A (en) | 1989-04-25 | 1996-03-19 | Iatron Laboratories, Inc. | Hybridomas producing monoclonal antibodies specific for C-reactive protein and methods for detection of C-reactive protein |
| JPH04505857A (ja) | 1989-06-27 | 1992-10-15 | ラッシュ―プレズビティリアン―セント ルークス メディカル センター | Ｃ反応性蛋白質に対するモノクローナル抗体 |
| US5051357A (en) | 1989-07-14 | 1991-09-24 | Board Of Trustees Operating Michigan State University | Method and assay using inactivation of factors Va and VIIIa by activated Protein C to diagnose thrombic disease or assay for Protein C and kit therefor |
| WO1991001383A1 (en) | 1989-07-14 | 1991-02-07 | Michigan State University | Method for diagnosing blood clotting disorders |
| EP0482088B1 (en) | 1989-07-20 | 1999-03-31 | Analytical Control Systems, Inc. | Improved stable coagulation controls |
| SU1691741A1 (ru) | 1989-08-25 | 1991-11-15 | Донецкий государственный медицинский институт | Способ прогнозировани геморрагических осложнений при травматической болезни |
| US4998535A (en) | 1989-09-05 | 1991-03-12 | Univ. of Washington New England Medical Center Hospitals, Inc. | Thrombolysis predictive instrument |
| US5262303A (en) | 1989-10-13 | 1993-11-16 | Trustees Of Boston University | Ligand/anti-ligand assays for adherent proteins |
| US5646046A (en) * | 1989-12-01 | 1997-07-08 | Akzo Nobel N.V. | Method and instrument for automatically performing analysis relating to thrombosis and hemostasis |
| IE904244A1 (en) | 1989-12-01 | 1991-06-05 | Akzo Nv | Direct fibrinogen assay |
| US5169786A (en) | 1989-12-19 | 1992-12-08 | Ortho Diagnostic Systems, Inc. | Method of determining levels of extrinsic and intrinsic clotting factors and protein c |
| JPH05506309A (ja) | 1990-04-17 | 1993-09-16 | アナリティカル・コントロール・システムズ・インコーポレーテッド | 凝固アッセイおよび試薬 |
| US5862304A (en) | 1990-05-21 | 1999-01-19 | Board Of Regents, The University Of Texas System | Method for predicting the future occurrence of clinically occult or non-existent medical conditions |
| US5218529A (en) | 1990-07-30 | 1993-06-08 | University Of Georgia Research Foundation, Inc. | Neural network system and methods for analysis of organic materials and structures using spectral data |
| CA2052316C (en) * | 1990-10-10 | 1997-12-23 | Edward A. Oakley | Sludge flow measuring system |
| JPH04254760A (ja) | 1991-01-30 | 1992-09-10 | Eiken Chem Co Ltd | 血清アミロイドａ標準物質、およびその設定方法 |
| US5221628A (en) | 1991-03-19 | 1993-06-22 | Northwestern University | Binding of aggregated immunoglobulin or immune complexes by serum amyloid P component |
| RU2012877C1 (ru) | 1991-04-01 | 1994-05-15 | Белорусский научно-исследовательский институт охраны материнства и детства | Способ прогнозирования синдрома дыхательных расстройств у недоношенных новорожденных |
| DE69122752T2 (de) | 1991-08-02 | 1997-04-10 | Grifols Grupo Sa | Verfahren und Vorrichtung zur Bestimmung der Gerinnungszeit von Blut und Plasma |
| AU2870992A (en) | 1991-10-04 | 1993-05-03 | Board Of Regents Of The University Of Nebraska, The | A soluble thrombomodulin-based one-stage assay for vitamin k-dependent coagulation-inhibiting proteins |
| US5716795A (en) | 1991-10-04 | 1998-02-10 | Matschiner; John T. | Thrombomodulin-based coagulometric assay of the protein C system |
| WO1993009438A1 (en) | 1991-11-04 | 1993-05-13 | Adeza Biomedical Corporation | Screening method for identifying women at increased risk for preterm delivery |
| JPH05180835A (ja) | 1991-12-27 | 1993-07-23 | S R L:Kk | ループスアンチコアグラントの測定方法 |
| US5318958A (en) | 1992-05-29 | 1994-06-07 | Queen's University At Kingston | Amyloid precursor protein |
| JP2934557B2 (ja) | 1992-07-10 | 1999-08-16 | 国際試薬株式会社 | 血液凝固時間測定方法とその装置 |
| JPH0636061A (ja) | 1992-07-21 | 1994-02-10 | Fujitsu Ltd | 階層型ニューラルネットワークの学習方式 |
| US5388164A (en) | 1992-08-19 | 1995-02-07 | Olympus Optical Co., Ltd. | Method for judging particle agglutination patterns using neural networks |
| JP3224607B2 (ja) | 1992-09-11 | 2001-11-05 | 株式会社アズウェル | 血液凝固第ｘｉｉｉ因子活性測定方法および該測定用試薬キット |
| US5369484A (en) | 1992-11-09 | 1994-11-29 | Akzo N.V. | Multiple discrete analyzer test apparatus and method |
| US5358852A (en) | 1992-12-21 | 1994-10-25 | Eastman Kodak Company | Use of calcium in immunoassay for measurement of C-reactive protein |
| RU2070327C1 (ru) | 1992-12-25 | 1996-12-10 | Безруков Александр Васильевич | Устройство для измерения времени свертывания крови |
| US5344754A (en) | 1993-01-13 | 1994-09-06 | Avocet Medical, Inc. | Assay timed by electrical resistance change and test strip |
| JP2938302B2 (ja) | 1993-02-25 | 1999-08-23 | 国際試薬株式会社 | 血液凝固時間測定方法とその装置 |
| JPH06249857A (ja) | 1993-02-26 | 1994-09-09 | Hitachi Ltd | 自動分析装置 |
| RU2061953C1 (ru) | 1993-03-10 | 1996-06-10 | Тюменский государственный медицинский институт МЗ РФ | Способ количественного определения общей коагуляционной активности тромбоцитов |
| US5670329A (en) | 1993-05-28 | 1997-09-23 | Cardiovascular Diagnostics, Inc. | Method and analytical system for performing fibrinogen assays accurately, rapidly and simply using a rotating magnetic field |
| ES2131543T3 (es) * | 1993-06-30 | 1999-08-01 | Stiftung Fur Diagnostische For | Medicion del tiempo de tromboplastina parcial activado (aptt) en una reaccion de una sola etapa. |
| AU688365B2 (en) | 1993-08-16 | 1998-03-12 | Biomerieux, Inc. | Method and instrument for automatically performing analysis relating to thrombosis and hemostasis |
| US5526111A (en) | 1993-08-31 | 1996-06-11 | Boehringer Mannheim Corporation | Method and apparatus for calculating a coagulation characteristic of a sample of blood a blood fraction or a control |
| US5472852A (en) | 1993-09-15 | 1995-12-05 | Oklahoma Medical Research Foundation | Assay for detection of selective Protein C inhibition by patients |
| US5473732A (en) | 1993-11-02 | 1995-12-05 | Chang; Hou-Mei H. | Relational artificial intelligence system |
| US5553616A (en) | 1993-11-30 | 1996-09-10 | Florida Institute Of Technology | Determination of concentrations of biological substances using raman spectroscopy and artificial neural network discriminator |
| US5856114A (en) | 1994-03-21 | 1999-01-05 | The University Of Vermont | Immunologic detection of factor VA fragments in hemorrhagic and thrombotic clinical settings |
| WO1995030154A1 (en) | 1994-04-28 | 1995-11-09 | Dade International Inc. | Calibrator for prothrombin time (pt) assays |
| WO1996006624A1 (en) | 1994-08-26 | 1996-03-07 | Immtech International, Inc. | A mutant protein and methods and materials for making and using it |
| US5504011A (en) | 1994-10-21 | 1996-04-02 | International Technidyne Corporation | Portable test apparatus and associated method of performing a blood coagulation test |
| SE9403833D0 (sv) * | 1994-11-08 | 1994-11-08 | Global Hemostasis Inst Mgr Ab | Analysförfarande och kit |
| US5705395A (en) | 1994-11-14 | 1998-01-06 | The Scripps Research Institute | Method for diagnosis of thrombotic disorders |
| US5567596A (en) | 1994-12-29 | 1996-10-22 | Research Foundation Of State University Of New York | Rapid assay of activators and inhibitors of clotting |
| US6207399B1 (en) | 1995-01-10 | 2001-03-27 | Hendrik Coenraad Hemker | Methods of determining endogenous thrombin potential (ETP) and thrombin substrates for use in said methods |
| US5708591A (en) | 1995-02-14 | 1998-01-13 | Akzo Nobel N.V. | Method and apparatus for predicting the presence of congenital and acquired imbalances and therapeutic conditions |
| US5646045A (en) * | 1995-05-17 | 1997-07-08 | Protein Technologies International | Cellulose in food matrix quantification |
| US6321164B1 (en) | 1995-06-07 | 2001-11-20 | Akzo Nobel N.V. | Method and apparatus for predicting the presence of an abnormal level of one or more proteins in the clotting cascade |
| US6429017B1 (en) * | 1999-02-04 | 2002-08-06 | Biomerieux | Method for predicting the presence of haemostatic dysfunction in a patient sample |
| US5780255A (en) | 1995-06-09 | 1998-07-14 | Instrumentation Laboratory, S.P.A. | Protein C pathway screening test |
| ATE190728T1 (de) | 1995-07-21 | 2000-04-15 | Trinity College Dublin | Verfahren zur quantitativen bestimmung menschlichen akutphasen-serum-amyloid-a-proteins; rekombinantes protein; spezifischer antikörper |
| US5766869A (en) | 1995-11-30 | 1998-06-16 | Ahs Hospital Corp. | Factor V ratio blood test for susceptibility to thromboembolism |
| EP0827425B1 (en) | 1996-03-22 | 2004-11-03 | Dade Behring Inc. | Combination reagent holding and test device |
| JPH1026621A (ja) | 1996-07-12 | 1998-01-27 | Dai Ichi Pure Chem Co Ltd | イムノアッセイ法 |
| US5684007A (en) | 1996-09-05 | 1997-11-04 | Otsuka Pharmaceutical Co., Ltd. | Methods for inhibiting cardiac fibroblast growth and cardiac fibrosis |
| JP3876022B2 (ja) | 1996-09-26 | 2007-01-31 | 生化学工業株式会社 | 血液凝固時間に影響を与える物質の定量方法 |
| US5981285A (en) | 1996-10-21 | 1999-11-09 | Carroll; Wallace E. | Method and apparatus for determining anticoagulant therapy factors |
| EP0841566A1 (en) | 1996-11-11 | 1998-05-13 | Pentapharm A.G. | Positive control plasma for lupus anticoagulant |
| ES2374621T3 (es) | 1997-04-02 | 2012-02-20 | The Brigham And Women's Hospital, Inc. | Medios para evaluar el perfil de riesgo de un individuo de sufrir una enfermedad ateroesclerótica. |
| US6010911A (en) | 1997-04-30 | 2000-01-04 | Medtronic, Inc. | Apparatus for performing a heparin-independent high sensitivity platelet function evaluation technique |
| DK0947585T3 (da) | 1998-03-19 | 2001-10-01 | Instrumentation Lab Spa | Forbedret in vitro-fremgangsmåde, kits og reagenser til screening for blodkoagulationsdefekter |
| US7179612B2 (en) * | 2000-06-09 | 2007-02-20 | Biomerieux, Inc. | Method for detecting a lipoprotein-acute phase protein complex and predicting an increased risk of system failure or mortality |
-
1999
- 1999-08-12 US US09/372,954 patent/US6429017B1/en not_active Expired - Lifetime
-
2000
- 2000-08-02 JP JP2001517176A patent/JP4733326B2/ja not_active Expired - Fee Related
- 2000-08-02 KR KR1020027001897A patent/KR20020021811A/ko not_active Ceased
- 2000-08-02 WO PCT/US2000/021022 patent/WO2001013125A1/en not_active Ceased
- 2000-08-02 AU AU66179/00A patent/AU6617900A/en not_active Abandoned
- 2000-08-02 CA CA2380622A patent/CA2380622C/en not_active Expired - Fee Related
- 2000-08-02 EP EP00953788A patent/EP1200837A4/en not_active Withdrawn
-
2002
- 2002-05-28 US US10/156,462 patent/US20030049851A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO2001013125A1 (en) | 2001-02-22 |
| JP4733326B2 (ja) | 2011-07-27 |
| EP1200837A1 (en) | 2002-05-02 |
| US20030049851A1 (en) | 2003-03-13 |
| CA2380622A1 (en) | 2001-02-22 |
| EP1200837A4 (en) | 2003-07-02 |
| US6429017B1 (en) | 2002-08-06 |
| JP2003507713A (ja) | 2003-02-25 |
| CA2380622C (en) | 2013-12-10 |
| AU6617900A (en) | 2001-03-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR20020021811A (ko) | 환자 표본에서 지혈 기능장애의 존재를 예견하기 위한 방법 | |
| AU2008201621B8 (en) | A method for predicting the presence of haemostatic dysfunction in a patient sample | |
| Hessam et al. | Correlation of inflammatory serum markers with disease severity in patients with hidradenitis suppurativa (HS) | |
| US20070155018A1 (en) | Method for detecting a lipoprotein-acute phase protein complex and predicting an increased risk of system failure or mortality | |
| US20140350129A1 (en) | Diagnostic assay to predict cardiovascular risk | |
| CN101384728B (zh) | 意识障碍患者的病态检测方法和检测试剂盒 | |
| AU2001266795A1 (en) | A method for detecting a lipoprotein-acute phase protein complex | |
| JP5060966B2 (ja) | 播種性血管内凝固症候群の病態把握方法 | |
| US7179612B2 (en) | Method for detecting a lipoprotein-acute phase protein complex and predicting an increased risk of system failure or mortality | |
| WO2014166508A1 (ru) | Способ определения функционального состояния системы гемостаза | |
| CN102121939A (zh) | 血小板血栓或脏器损伤的检测方法 | |
| EP4636404A2 (en) | Method for evaluating risk of acute cerebral vascular disease using soluble clec2 | |
| KR20140023260A (ko) | Cartilage Acidic Protein 1 단백질에 의한 뇌경색의 검사 방법 | |
| El-Hawy et al. | Urinary biomarkers of early kidney injury in children with beta-thalassemia | |
| US20240288435A1 (en) | Method for predicting risk for thrombosis in cancer patient using soluble clec2 | |
| AU2005201099A1 (en) | Method for predicting the presence of haemostatic dysfunction in a patient sample | |
| JP2011237402A (ja) | ガレクチン−３結合蛋白質による脳梗塞の検査方法 | |
| WO2025075139A1 (ja) | 可溶型ｃｌｅｃ－２を用いた脳心血管・腎イベントの長期的発症ハイリスク評価法 | |
| HK40105374A (en) | Method for evaluating risk of acute cerebral vascular disease using soluble clec2 | |
| JP2012107932A (ja) | Ｃｌｕｓｔｅｒｉｎ蛋白質による脳梗塞の検査方法 | |
| JP2020153767A (ja) | 被検動物における急性期のｂａｄの発症可能性の評価方法及び急性期の分岐粥腫型梗塞の診断薬 | |
| JP2012107931A (ja) | Ｂｃｌ−ＸＬ蛋白質による脳梗塞の検査方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20020209 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| A201 | Request for examination | ||
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20050725 Comment text: Request for Examination of Application |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20060628 Patent event code: PE09021S01D |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20061023 Patent event code: PE09021S01D |
|
| E601 | Decision to refuse application | ||
| PE0601 | Decision on rejection of patent |
Patent event date: 20070430 Comment text: Decision to Refuse Application Patent event code: PE06012S01D Patent event date: 20061023 Comment text: Notification of reason for refusal Patent event code: PE06011S01I Patent event date: 20060628 Comment text: Notification of reason for refusal Patent event code: PE06011S01I |